Eledon Pharmaceuticals, Inc.
ELDN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $359 | $374 | $373 | $195 |
| Gross Profit | -$359 | -$374 | -$373 | -$195 |
| % Margin | – | – | – | – |
| R&D Expenses | $51,964 | $30,312 | $27,080 | $23,735 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $18,254 | $12,314 | $12,327 | $12,937 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $70,218 | $42,626 | $39,407 | $36,672 |
| Operating Income | -$70,577 | -$43,000 | -$39,780 | -$36,867 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $34,824 | -$73,537 | -$48,186 | $7 |
| Pre-Tax Income | -$35,753 | -$116,537 | -$87,966 | -$36,860 |
| Tax Expense | $431 | $0 | $0 | -$2,354 |
| Net Income | -$36,184 | -$116,537 | -$87,966 | -$34,506 |
| % Margin | – | – | – | – |
| EPS | -0.75 | -0.002 | -6.13 | -2.33 |
| % Growth | -46,775% | 100% | -163.1% | – |
| EPS Diluted | -0.75 | -1.64 | -6.13 | -2.33 |
| Weighted Avg Shares Out | 48,544 | 24,619 | 14,285 | 14,820 |
| Weighted Avg Shares Out Dil | 48,544 | 24,619 | 14,285 | 14,820 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $359 | $374 | $373 | $195 |
| EBITDA | -$35,394 | -$116,163 | -$87,593 | -$36,665 |
| % Margin | – | – | – | – |